1 |
Stevens RD, Dowdy DW, Michaels RK, et al. Neuromuscular dysfunction acquired in critical illness: a systematic review[J]. Intensive Care Med, 2007, 33(11): 1876-1891.
|
2 |
Sharshar T, Bastuji-Garin S, Stevens RD, et al. Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care unit and hospital mortality[J]. Crit Care Med, 2009, 37(12): 3047-3053.
|
3 |
Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness[J]. Crit Care Med, 2009, 37(10 Suppl): S299-S308.
|
4 |
Fan E, Dowdy DW, Colantuoni E, et al. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study[J]. Crit Care Med, 2014, 42(4): 849-859.
|
5 |
Ali NA, O′Brien JJ, Hoffmann SP, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients[J]. Am J Respir Crit Care Med, 2008, 178(3): 261-268.
|
6 |
Mador MJ, Deniz O, Aggarwal A, et al. Quadriceps fatigability after single muscle exercise in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2003, 168(1): 102-108.
|
7 |
Bednarik J, Vondracek P, Dusek L, et al. Risk factors for critical illness polyneuromyopathy[J]. J Neurol, 2005, 252(3): 343-351.
|
8 |
Wintermann GB, Rosendahl J, Weidner K, et al. Self-reported fatigue following intensive care of chronically critically ill patients: a prospective cohort study[J]. J Intensive Care, 2018, 6: 27.
|
9 |
Friedrich O, Reid MB, Vanden Berghe G, et al. The Sick and the Weak: Neuropathies/Myopathies in the Critically Ⅲ[J]. Physiol Rev, 2015, 95(3): 1025-1109.
|
10 |
Becker RE. Remembering Sir William Osler 100 years after his death:what can we learn from his legacy?[J]. Lancet, 2014, 384(9961): 2260-2263.
|
11 |
Zorowitz RD. ICU-Acquired Weakness: A Rehabilitation perspective of diagnosis, treatment, and functional management[J]. Chest, 2016, 150(4): 966-971.
|
12 |
邹文茂,刘芙蓉,李景辉. ICU获得性肌无力动物模型的研究现状[J]. 中南大学学报(医学版), 2018, 43(6): 691-696.
|
13 |
唐 章,徐朝霞,李 亚,等. 构建脓毒症大鼠ICU获得性衰弱模型的研究[J]. 西南国防医药,2019, 29(6).
|
14 |
Wollersheim T, Woehlecke J, Krebs M, et al. Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness[J]. Intensive Care Med, 2014, 40(4): 528-538.
|
15 |
Cohen S, Zhai B, Gygi SP, et al. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy[J]. J Cell Biol, 2012, 198(4): 575-589.
|
16 |
Tintignac LA, Lagirand J, Batonnet S, et al. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase[J]. J Biol Chem, 2005, 280(4): 2847-2856.
|
17 |
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family[J]. Annu Rev Immunol, 2009, 27: 519-550.
|
18 |
Petrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration[J]. Cell Death Differ, 2007, 14(9): 1583-1589.
|
19 |
Bryan NB, Dorfleutner A, Rojanasakul Y, et al. Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain[J]. J Immunol, 2009, 182(5): 3173-3182.
|
20 |
Gao M, Zhang P, Huang L, et al. Is NLRP3 or NLRP6 inflammasome activation associated with inflammation-related lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide?[J]. Ecotoxicol Environ Saf, 2019, 185: 109687.
|